PACIRA BIOSCIENCES, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
PACIRA BIOSCIENCES, INC. (PCRX) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $1.30 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-04-28
- PACIRA BIOSCIENCES, INC. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2020-12-31 was -$2.00M, a 122.73% decline year-over-year.
- PACIRA BIOSCIENCES, INC. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2020-09-30 was -$124.60M.
- PACIRA BIOSCIENCES, INC. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2019-12-31 was $8.80M.
- PACIRA BIOSCIENCES, INC. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2019-09-30 was $0.00.
- PACIRA BIOSCIENCES, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $1.30M.
- PACIRA BIOSCIENCES, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $2.60M, a 33.33% decline from fiscal 2022.
- PACIRA BIOSCIENCES, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $3.90M, a 76.36% decline from fiscal 2021.
- PACIRA BIOSCIENCES, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2021 was $16.50M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 3 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 6 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 9 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $1.30M 10-K · filed 2026-02-26 | ||||
| 2024-12-31 | $163.20M DEFC14A · filed 2026-04-28 | $700.00K 10-K · filed 2025-02-27 | |||
| 2023-12-31 | $2.60M 10-K · filed 2025-02-27 | ||||
| 2022-12-31 | $3.90M 10-K · filed 2024-02-29 | ||||
| 2021-12-31 | $16.50M 10-K · filed 2023-02-28 | -$16.50M 10-K · filed 2022-02-28 | |||
| 2020-12-31 | -$2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$126.60M derived: sum of 2 quarters · filed 2023-02-28 | -$126.60M 10-K · filed 2023-02-28 | ||
| 2020-09-30 | -$124.60M 10-Q · filed 2021-11-03 | -$124.60M 10-Q · filed 2021-11-03 | |||
| 2019-12-31 | $8.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $8.80M derived: sum of 2 quarters · filed 2021-03-01 | $7.00M derived: sum of 3 quarters · filed 2021-03-01 | $7.00M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | -$1.80M derived: sum of 2 quarters · filed 2020-10-30 | -$1.80M 10-Q · filed 2020-10-30 | ||
| 2019-06-30 | -$1.80M 10-Q · filed 2020-08-06 | -$1.80M 10-Q · filed 2020-08-06 | |||
| 2018-12-31 | -$1.60M 10-K · filed 2020-02-21 | $1.60M 10-K · filed 2019-02-28 | |||
| 2017-12-31 | -$28.50M 10-K · filed 2019-02-28 | ||||
| 2016-12-31 | $800.00K 10-K · filed 2019-02-28 | $16.60M 10-K · filed 2017-03-01 | |||
| 2015-12-31 | $800.00K 10-K · filed 2018-02-28 | ||||
| 2014-12-31 | $9.90M 10-K · filed 2017-03-01 | $9.90M 10-K · filed 2016-02-25 | |||
| 2013-12-31 | $17.50M 10-K · filed 2016-02-25 | ||||
| 2012-12-31 | $20.70M 10-K · filed 2015-02-24 | ||||
| 2011-12-31 | $16.60M 10-K · filed 2014-02-25 | ||||
| 2010-12-31 | $12.20M 10-K · filed 2013-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |